Statement of Organization, Functions, and Delegations of Authority, 13126 [2023-04009]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
13126
Federal Register / Vol. 88, No. 41 / Thursday, March 2, 2023 / Notices
in the body of your comments and you
must identify the information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT: SheChia Jankowski, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 240–
402–5343, email: ODAC@fda.hhs.gov, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area). A notice in
the Federal Register about last-minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check
FDA’s website at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. The
committee will discuss supplemental
new drug application (sNDA) 208558/S–
025, for LYNPARZA (olaparib) tablets,
submitted by AstraZeneca
Pharmaceuticals LP. The proposed
indication (use) for this product is in
combination with abiraterone and
prednisone or prednisolone for the
treatment of adult patients with
metastatic castration-resistant prostate
cancer (mCRPC).
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
VerDate Sep<11>2014
18:21 Mar 01, 2023
Jkt 259001
be made publicly available on FDA’s
website at the time of the advisory
committee meeting. Background
material and the link to the online
teleconference meeting room will be
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link. The meeting will include slide
presentations with audio components to
allow the presentation of materials in a
manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see ADDRESSES) on or before
April 14, 2023, will be provided to the
committee. Oral presentations from the
public will be scheduled between
approximately 2:15 p.m. to 3:15 p.m.
Eastern Time. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 6,
2023. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 7, 2023.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact She-Chia
Jankowski (see FOR FURTHER
INFORMATION CONTACT) at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Dated: February 24, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–04268 Filed 3–1–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions,
and Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Secretary of Health and
Human Services delegates to the Food
and Drug Administration (FDA)
Commissioner the authorities vested in
the Secretary of Health and Human
Services (the Secretary) under section
3855 of the Coronavirus Aid, Relief, and
Economic Security (CARES) Act, as
amended, to send annual letters to
Congress regarding the progress of FDA
in: evaluating the Over-the-Counter
Monograph M012: Cold, Cough, Allergy,
Bronchodilator, and Antiasthmatic Drug
Products for Over-the-Counter Human
Use with respect to children under the
age of 6, and as appropriate, revising
that monograph through the order
process of section 505G(b) of the Federal
Food, Drug, and Cosmetic Act to
address such children. These authorities
may be redelegated. Exercise of this
authority shall be in accordance with
established policies, procedures,
guidelines, and regulations as
prescribed by the Secretary.
DATES: This authority delegation was
approved by the Secretary on February
22, 2023.
SUMMARY:
Dated: February 22, 2023.
Xavier Becerra,
Secretary, Department of Health and Human
Services.
[FR Doc. 2023–04009 Filed 3–1–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–D–0202]
Potency Assay Considerations for
Monoclonal Antibodies and Other
Therapeutic Proteins Targeting Viral
Pathogens; Draft Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
E:\FR\FM\02MRN1.SGM
02MRN1
]]>Agencies
[Federal Register Volume 88, Number 41 (Thursday, March 2, 2023)]
[Notices]
[Page 13126]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04009]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions, and Delegations of
Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Secretary of Health and Human Services delegates to the
Food and Drug Administration (FDA) Commissioner the authorities vested
in the Secretary of Health and Human Services (the Secretary) under
section 3855 of the Coronavirus Aid, Relief, and Economic Security
(CARES) Act, as amended, to send annual letters to Congress regarding
the progress of FDA in: evaluating the Over-the-Counter Monograph M012:
Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products
for Over-the-Counter Human Use with respect to children under the age
of 6, and as appropriate, revising that monograph through the order
process of section 505G(b) of the Federal Food, Drug, and Cosmetic Act
to address such children. These authorities may be redelegated.
Exercise of this authority shall be in accordance with established
policies, procedures, guidelines, and regulations as prescribed by the
Secretary.
DATES: This authority delegation was approved by the Secretary on
February 22, 2023.
Dated: February 22, 2023.
Xavier Becerra,
Secretary, Department of Health and Human Services.
[FR Doc. 2023-04009 Filed 3-1-23; 8:45 am]
BILLING CODE 4164-01-P
